Home Cart Sign in  
Chemical Structure| 139262-76-3 Chemical Structure| 139262-76-3

Structure of H2L5186303
CAS No.: 139262-76-3

Chemical Structure| 139262-76-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

H2L5186303 is an effective and selective antagonist of the LPA2 receptor (lysophosphatidic acid 2 receptor) with an IC50 of 9 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of H2L5186303

CAS No. :139262-76-3
Formula : C26H20N2O8
M.W : 488.45
SMILES Code : O=C(O)/C=C\C(NC1=CC=C(OC2=CC=CC(OC3=CC=C(NC(/C=C\C(O)=O)=O)C=C3)=C2)C=C1)=O

Safety of H2L5186303

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of H2L5186303

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RBL-2H3 rat basophilic leukemia cells 10 µM 30 minutes Inhibited antigen-induced mast cell degranulation as assessed by β-hexosaminidase activity Int J Mol Sci. 2022 Aug 28;23(17):9745
primary cortical cells 10 µM 4-7 minutes Evaluate the effect of LPA2/3 receptor antagonist on LPA-induced Ca2+ signals, partially blocked LPA-induced Ca2+ signals Sci Rep. 2020 Feb 14;10(1):2649

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Ovalbumin (OVA)-induced allergic asthma model Intraperitoneal injection 1 mg/kg Single administration 30 min before OVA sensitization or challenge H2L5186303 significantly suppressed airway hyperresponsiveness, inflammatory cell infiltration, mucin production and Th2 cytokine levels when administered before both antigen sensitization and challenge Int J Mol Sci. 2022 Aug 28;23(17):9745

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.05mL

0.41mL

0.20mL

10.24mL

2.05mL

1.02mL

20.47mL

4.09mL

2.05mL

 

Historical Records

Categories